Nordic Biomed Innovation AB joined MOU with ALTEOGEN Inc. in South Korea

On the 5th of January 2018 Nordic Biomed Innovation AB and ALTEOGEN Inc. in Daejeon in South Korea joined an MOU. The goal of the MOU is to establish a platform to cooperate in disease diagnostics and product marketing.

ALETOGEN Inc. is a renowned biopharmaceutical company, developing and marketing the next generation long-acting biobetters and biosimilars, e.g. long-acting therapeutic proteins (NeP fusion technology), trastuzumab-drug conjugate, anti-breast cancer therapeutic (NexMab ADC technology) with global networks.

For more information about ALTEOGEN Inc.: www.alteogen.com